Abstract
Background: The aim of the article was to systematically review published data about the relationship between prostate-specific antigen (PSA) kinetics, including PSA doubling time (PSAdt) and PSA velocity (PSAvel), and detection rate (DR) of positron emission tomography/computed tomography (PET/CT) using radiolabelled choline in restaging prostate cancer (PCa).
Methods: A comprehensive literature search of studies published through July 2013 regarding the relationship between PSA kinetics and DR of radiolabelled choline PET/CT was carried out. Furthermore, a meta-analysis was performed in order to establish the DR of radiolabelled choline PET/CT using different cut-off values of PSAdt (≤ or >6 months) and PSAvel [>1 or ≤1 ng/(mL year) and >2 or ≤2 ng/(mL year)]. Moreover, a pooled analysis to establish whether PSAdt and PSAvel (using the abovementioned cut-off values) may predict positive PET/CT results was carried out.
Results: Fourteen articles were selected. The pooled DR of radiolabelled choline PET/CT in restaging PCa was 58% [95% confidence interval (CI) 55–60]. Most articles reported a relationship between PSA kinetics and DR of PET/CT. Pooled DR of radiolabelled choline PET/CT increased to 65% (95% CI 58–71) when PSAdt was ≤6 months and to 71% (95% CI 66–76) and 77% (95% CI 71–82) when PSAvel was >1 or >2 ng/(mL year), respectively. PSAdt ≤6 months and PSAvel >1 or >2 ng/(mL year) proved to be relevant factors in predicting the positive result of radiolabelled choline PET/CT.
Conclusions: Due to the strong relationship between PSA kinetics and DR of radiolabelled choline PET/CT, beyond PSA values, PSAdt and PSAvel should be taken into account in the selection of PCa patients who should undergo radiolabelled choline PET/CT for restaging.
References
1. Marta GN, Hanna SA, Fernandes da Silva JL, Carvalho Hde A. Screening for prostate cancer: an updated review. Expert Rev Anticancer Ther 2013;13:101–8.10.1586/era.12.154Search in Google Scholar
2. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al., European Association of Urology. EAU guidelines on prostate cancer: part 1. Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61–71.10.1016/j.eururo.2010.10.039Search in Google Scholar
3. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer: part II. Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572–83.10.1016/j.eururo.2011.01.025Search in Google Scholar
4. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517–23.10.1016/S0022-5347(05)63946-8Search in Google Scholar
5. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D′Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177:540–5.10.1016/j.juro.2006.10.097Search in Google Scholar PubMed
6. Roach M III, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965–74.10.1016/j.ijrobp.2006.04.029Search in Google Scholar PubMed
7. O′Brien MF, Cronin AM, Fearn PA, Smith B, Stasi J, Guillonneau B, et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol 2009;27:3591–710.1200/JCO.2008.19.9794Search in Google Scholar PubMed PubMed Central
8. Schiavina R, Brunocilla E, Borghesi M, Vagnoni V, Castellucci P, Nanni C, et al. Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: How to differentiate local from systemic disease? The urologist point of view. Rev Esp Med Nucl Imagen Mol 2013;32:310–3.Search in Google Scholar
9. Khan MA, Carter HB, Epstein JI, Miller MC, Landis P, Walsh PW, et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 2003;170:2274–8.10.1097/01.ju.0000097124.21878.6bSearch in Google Scholar PubMed
10. Svatek RS, Shulman M, Choudhary PK, Benaim E. Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 2006;106:1047–53.10.1002/cncr.21696Search in Google Scholar PubMed
11. Evangelista L, Zattoni F, Guttilla A, Saladini G, Zattoni F, Colletti PM, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med 2013;38:305–14.10.1097/RLU.0b013e3182867f3cSearch in Google Scholar PubMed
12. Treglia G, Giovannini E, Di Franco D, Calcagni ML, Rufini V, Picchio M, et al. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Ann Nucl Med 2012;26:451–61.10.1007/s12149-012-0602-7Search in Google Scholar
13. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999;12:413–39.10.1002/(SICI)1099-1492(199911)12:7<413::AID-NBM587>3.0.CO;2-USearch in Google Scholar
14. DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001;42:1805–14.Search in Google Scholar
15. Evangelista L, Cervino AR, Burei M, Gregianin M, Saladini G, Marzola MC, et al. Comparative studies of radiolabeled choline positron emission tomography, histology of primary tumor and other imaging modalities in prostate cancer: a systematic review and meta-analysis. Clin Transl Imaging 2013;1;99–109.10.1007/s40336-013-0016-0Search in Google Scholar
16. Giovacchini G, Breeuwsma AJ. Restaging prostate cancer patients with biochemical failure with PET/CT and radiolabeled choline. Q J Nucl Med Mol Imaging 2012;56:354–66.Search in Google Scholar
17. Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T, et al. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med 2013;54:833–40.10.2967/jnumed.112.110148Search in Google Scholar
18. Ceci F, Castellucci P, Mamede M, Schiavina R, Rubello D, Fuccio C, et al. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. Eur J Nucl Med Mol Imaging 2013;40:149–55.10.1007/s00259-012-2272-zSearch in Google Scholar
19. Giovacchini G, Picchio M, Garcia-Parra R, Mapelli P, Briganti A, Montorsi F, et al. [11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen. J Urol 2013;189:105–10.10.1016/j.juro.2012.09.001Search in Google Scholar
20. Mamede M, Ceci F, Castellucci P, Schiavina R, Fuccio C, Nanni C, et al. The role of 11C-choline pet imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL. Clin Nucl Med 2013;38:e342–5.10.1097/RLU.0b013e31829af913Search in Google Scholar
21. Marzola MC, Chondrogiannis S, Ferretti A, Grassetto G, Rampin L, Massaro A, et al. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution. Clin Nucl Med 2013;38:e26–32.10.1097/RLU.0b013e318266cc38Search in Google Scholar
22. Rybalov M, Breeuwsma AJ, Leliveld AM, Pruim J, Dierckx RA, de Jong IJ. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-choline positron emission tomography in recurrent prostate cancer. World J Urol 2013;31:319–23.10.1007/s00345-012-0908-zSearch in Google Scholar
23. Breeuwsma AJ, Rybalov M, Leliveld AM, Pruim J, de Jong IJ. Correlation of [11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy. Q J Nucl Med Mol Imaging 2012;56:440–6.Search in Google Scholar
24. Giovacchini G, Picchio M, Parra RG, Briganti A, Gianolli L, Montorsi F, et al. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy. Clin Nucl Med 2012;37: 325–31.10.1097/RLU.0b013e31823363b0Search in Google Scholar
25. Graute V, Jansen N, Ubleis C, Seitz M, Hartenbach M, Scherr MK, et al. Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging 2012;39:271–82.10.1007/s00259-011-1970-2Search in Google Scholar PubMed
26. Schillaci O, Calabria F, Tavolozza M, Caracciolo CR, Finazzi Agrò E, Miano R, et al. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy. Eur J Nucl Med Mol Imaging 2012;39:589–96.10.1007/s00259-011-2030-7Search in Google Scholar PubMed
27. Casamassima F, Masi L, Menichelli C, Bonucci I, Casamassima E, Lazzeri M, et al. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 2011;97:49–55.10.1177/030089161109700110Search in Google Scholar
28. Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, et al. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging 2011;38:55–63.10.1007/s00259-010-1604-0Search in Google Scholar PubMed
29. Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, et al. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010;37:1106–16.10.1007/s00259-010-1403-7Search in Google Scholar PubMed
30. Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, et al. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009;50:1394–400.10.2967/jnumed.108.061507Search in Google Scholar PubMed
31. Sadeghi R, Treglia G. Meta-analyses and systematic reviews on PET and PET/CT in oncology: the state of the art. Clin Transl Imaging 2013;1:73–5.10.1007/s40336-013-0013-3Search in Google Scholar
32. Castellucci P, Picchio M. 11C-Choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging 2013;40:S36–40.10.1007/s00259-013-2377-zSearch in Google Scholar PubMed
33. Ratib O. PET/MRI: a new era in multimodality molecular imaging. Clin Transl Imaging 2013;1:5–10.10.1007/s40336-013-0003-5Search in Google Scholar
34. Pace L, Nicolai E, Aiello M, Catalano OA, Salvatore M. Whole-body PET/MRI in oncology: current status and clinical applications. Clin Transl Imaging 2013;1:31–44.10.1007/s40336-013-0012-4Search in Google Scholar
©2014 by Walter de Gruyter Berlin/Boston
